BTIG reiterated coverage on OrthoPediatrics with a new price target
$KIDS
Medical/Dental Instruments
Health Care
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/25/2024 | $39.00 → $31.00 | Buy → Hold | Truist |
| 3/3/2022 | $83.00 → $65.00 | Buy | Needham |
| 12/22/2021 | $75.00 → $68.00 | Buy | BTIG |
| 12/21/2021 | $78.00 → $75.00 | Buy | Truist Securities |
| 8/6/2021 | $70.00 → $77.00 | Market Outperform | JMP Securities |
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
WARSAW, Ind., March 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. Event:24th Annual Needham Virtual Healthcare ConferenceFormat:Fireside ChatDate:Tuesday, April 8, 2025Time:9:30 am ET An audio webcast of the discussion will be available online at the OrthoPediatrics' investor relations website, http://ir.orthop
WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was selected as one of the 2025 Best Places to Work in Indiana. This is the 9th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce. OrthoPediatrics President & CEO David Bailey commented, "I'm so proud of our organization for being named one of the "Best Places to Work" in Indiana for a 9th time. Our leadership team is committed to fostering an engaging and inclusive culture, and meaningful career experiences for all our
WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads Pediatric Device Consortium (CPDC). This collaboration aligns with the Company's cause of improving the lives of children by supporting the development and commercialization of innovative pediatric medical devices. The Crossroads Pediatric Device Consortium is a multi-institutional initiative focused on accelerating the development, approval, and availability of medical devices designed specifically for pediatric patients. Founding member
Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 & Recent Business Highlights Helped a new record of over 34,000 children in the fourth quarter 2024 and approximately 138,000 for full year 2024, bringing the total to over 1.14 million since the i
WARSAW, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, March 4, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads Pediatric Device Consortium (CPDC). This collaboration aligns with the Company's cause of improving the lives of children by supporting the development and commercialization of innovative pediatric medical devices. The Crossroads Pediatric Device Consortium is a multi-institutional initiative focused on accelerating the development, approval, and availability of medical devices designed specifically for pediatric patients. Founding member
WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the "Alliance for Pediatric Device Innovation" (APDI), to advice the development and commercialization of medical devices designed for children. Along with Children's National, APDI consortium members include Johns Hopkins University, CIMIT at Mass General Brigham, Tufts Medical Center and Medstar Health Research Institute. The Company will serve as APDI's strategic advisor and role model for devic
New CEO Paul Mraz also joins FzioMed Inc.'s Board of Directors; Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, Calif., Jan. 3, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors. Mraz's appointment became effective Jan. 1, 2023, commensurate with the retirement of John Krelle who served in the leadership role since 2005. "On behalf of the Board of Directors, I want to thank John for
Truist downgraded OrthoPediatrics from Buy to Hold and set a new price target of $31.00 from $39.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $65.00 from $83.00 previously
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
10-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)